Longboard Pharmaceuticals’ epilepsy drug candidate bexicaserin met the main efficacy goal of its Phase 1b/2a study along with safety data suggesting a potential edge over current treatments. With Longboard now preparing to advance to Phase 3 testing, its stock price soared more than 300%.
Iambic Therapeutics brings together software engineers and drug-hunting scientists, all sharing the goal of using artificial intelligence to optimize properties of small molecule drugs. The startup will apply its Series B financing to a cancer drug pipeline that includes two candidates on track for the clinic in 2024.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Avalon BioVentures unveiled new portfolio company Arialys Therapeutics. The startup’s lead program, an antibody from Astellas Pharma, is a potential treatment for anti-NMDA receptor encephalitis (ANRE), a rare autoimmune inflammatory disorder.
Turnstone Biologics isn’t the only cell therapy biotech focused on tumor-infiltrating lymphocytes. With $80 million in IPO cash, it can continue clinical trials that could show whether its approach to TILs has advantages.
In addition to airports, the company's Google Glass-enabled technology has been used to help individuals navigate college campuses, train stations, and city centers.
The goal of the La Jolla, California-based company, is to make genomic testing readily accessible and affordable for everyone through employer plans.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
J. Craig Venter will step down as CEO of his ambitious genomics-driven biotech Human Longevity, effective January 9.
DermTech has a biopsy-free approach to test for melanoma - using an adhesive patch to collect skin cells and test if the RNA expression is consistent with cancer.
Nick Valeriani will retire as CEO of West Health in September, and be replaced by current COO Shelley Lyford, who also is president and CEO the Gary and Mary West Foundation, the entity that sponsors West Health.
The research institute already has strong ties with the pharmaceutical industry. This donation is reflective of an overall increase in translational medicine - in these changing times, the biopharma industry has a growing reliance on academia
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.